Salute e Benessere

NABR Applauds CITES Standing Committee's Decision Not to Enact Trade Suspension…

During the CITES Standing Committee meeting in Geneva, Switzerland, not a single country spoke in favor of the Secretariat's recommendation for a suspension of trade based on flawed claims regarding Cambodia's macaque exports. Instead, multiple nations—including Japan, Canada, and the United States—emphasized the importance of reviewing Cambodia's newly submitted information before any actions were taken. The committee's decision will allow the CITES Secretariat to conduct a thorough assessment…
PR Newswire
04/02/2025

Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29%…

Key Takeaways from the Peptide-drug Conjugate Market Report Key Takeaways from the Peptide-drug Conjugate Market Report To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in theGlobal Peptide-drug Conjugate Market Report Peptide-drug Conjugate Overview Peptide-drug conjugates (PDCs) are an emerging class of targeted therapeutics that combine the specificity of peptides with the potent efficacy of cytotoxic drugs...
PR Newswire
04/02/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 01/31/2025100,093,87388,660,571 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief...
Nasdaq GlobeNewswire
04/02/2025

Neutrogena® Introduces Tate McRae as Global Brand Ambassador

Neutrogena's new campaign highlights products from its award-winning Hydro Boost range, including the Water Gel. This commemorates Hydro Boost's 10th anniversary as one of the brand's top-selling facial moisturizers, which jumpstarted the hyaluronic acid ingredient category. On average, a jar of Neutrogena Hydro Boost Water Gel is sold every two seconds worldwide1. Neutrogena's new campaign highlights products from its award-winning Hydro Boost range, including the Water Gel. This…
PR Newswire
04/02/2025

FDA approves Roche's Susvimo as the first and only continuous delivery treatment…

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year, Susvimo may help people with DME maintain their visionApproval marks the second indication for Susvimo in addition to neovascular or 'wet' age-related macular degeneration (nAMD)Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug...
Nasdaq GlobeNewswire
04/02/2025

LBB Specialties Partners with Kerry Group to Launch Innovative Ingredients to…

"We are honored to partner with Kerry, a brand synonymous with technology, innovation, and quality in the Food & Nutrition industry, as their key Personal Care distributor—launching their technology and expertise into the PC market," said Christopher Nork, Senior Vice President of LBB Specialties Care. "As consumer demand grows for natural, innovative, sensory-rich and sustainable formulations, this partnership aligns with our customer excellence pillar and resources to our…
PR Newswire
04/02/2025

Mass Spectrometry Market to Hit USD 9.62 Billion by 2030 with 7.2% CAGR |…

Browse in-depth TOC on "Mass Spectrometry Market" Browse in-depth TOC on "Mass Spectrometry Market" 400 - Tables 50 - Figures 250 - Pages Based on product type, the mass spectrometry is segmented into instrument and software & services. During the forecast period, the instrument is expected to dominate the mass spectrometry market. The growth of mass spectrometry instruments will be driven by the procedural benefits offered by LC-MS and triple-quadrupole mass...
PR Newswire
04/02/2025

Surplus Solutions Expands Global Offerings with Refurbished Analytical and…

Certified Surplus™ refurbished equipmentand a growing portfolio ofmedical equipment, now available to customers worldwide. This milestone, made possible through the company's 2024 acquisition of FAMECO, a European leader in laboratory and medical equipment refurbishment, strengthens our ability to deliver high-quality refurbished solutions globally.To support its expansion, Surplus Solutions has introduced a newly redesigned website athttps://ssllc.com, a refreshed brand identity,...
Nasdaq GlobeNewswire
04/02/2025

Coloplast Finance B.V. - Interim Financial Report, Q1 2024/25

2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin 1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%.Growth in Chronic Care was driven...
Nasdaq GlobeNewswire
04/02/2025

Newsweek and BrandSpark International announce the 3rd annual rankings of the…

"In today's uncertain economic landscape, trust has become a cornerstone of consumer decision-making. With shoppers increasingly mindful of where they spend their money, brands that deliver consistent quality, reliability, and value are at the top", says Robert Levy, President of BrandSpark International. "In today's uncertain economic landscape, trust has become a cornerstone of consumer decision-making. With shoppers increasingly mindful of where they spend their money, brands…
PR Newswire
04/02/2025

Patient Advocates from NCCN Guidelines Panels Share Their 'United by Unique'…

World Cancer Day 2025 marks the start of the 'United by Unique' campaign to highlight how every experience with cancer is unique, even as people touched by cancer are united by shared goals. The campaign calls for a fundamental shift in cancer care worldwide towards a people-centered approach. World Cancer Day 2025 marks the start of the 'United by Unique' campaign to highlight how every experience with cancer is unique, even as people touched by cancer are united by shared goals. The…
PR Newswire
04/02/2025

Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility…

thFebruary 2025Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities in Belgium, Spain, the Netherlands, and Sweden, today announced that it has successfully completed the acquisition of Catalent's state-of-the-art drug product manufacturing facility in Somerset, New Jersey.This acquisition marks a significant milestone in Ardena's strategic expansion into North America,...
Nasdaq GlobeNewswire
04/02/2025

Waters ElectroForce Apex 1 Instrument Offers Increased Versatility, Simplicity…

"As an additive manufacturing company, we build 3D-printed polymer parts that are increasingly being used in highly demanding applications where strength and durability are essential. After one short training session, we were able to use the ElectroForce Apex 1 Instrument to easily conduct tensile and fatigue testing to characterize our new materials," said Javier Ramos, Chief Technology Officer for Inkbit Corporation. "The ease of use and quick time to results have given us the…
PR Newswire
04/02/2025

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 4 February 2025– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
04/02/2025

Coloplast A/S - Allocation of Share Options

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities.The below transactions concern allocation of share options.For further details, reference is made to Coloplast's Remuneration Policy. The policy is available on the group website at this address:...
Nasdaq GlobeNewswire
04/02/2025

Servier to Adopt Veeva RIM to Streamline and Advance its Global Regulatory…

"Unifying regulatory data, documents, and processes on Veeva RIM will help Servier streamline operations and accelerate patient access to new medicines," said Alexandra Pearce, global head, worldwide regulatory affairs at Servier. "With Veeva, we have a reliable partner to help us scale and connect teams while driving better regulatory oversight and reducing time to submission." "Unifying regulatory data, documents, and processes on Veeva RIM will help Servier streamline…
PR Newswire
04/02/2025

INAUGURAL LEVERAGED FINANCE FIGHTS MELANOMA LONDON RAISES £1.4 MILLION…

"The £1.4M raised by LFFM London will have a transformative impact on our mission," said Stephanie Kauffman, president of the Melanoma Research Alliance. "This generous support allows us to continue our investments in brilliant UK-based researchers providing them with crucial resources they need to push the boundaries of melanoma research, driving forward innovations that bring us closer to a cure and improve patient outcomes in the UK and around the world." "The £1.4M…
PR Newswire
04/02/2025

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic…

This marks the first clinical study from the Alys pipeline, which includes a broad portfolio of assets targeting unmet needs in additional indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, or systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. This marks the first clinical study from the Alys pipeline, which includes a broad portfolio of assets targeting unmet needs in additional indications…
PR Newswire
04/02/2025

Bayer Foundation Women Entrepreneurs Award: Applications Open for Innovators in…

Standout winners in 2024 include: Standout winners in 2024 include: Discover more from the2024 winners and the extraordinary impact they are creating in their regions.Applications are now open, and will close on February 18, 2025. "Through this partnership, we provide valuable support specifically tailored to the needs of women entrepreneurs and their businesses. We also foster collaboration to accelerate change in health and food security," notedPetr Skvaril,...
PR Newswire
04/02/2025

EAACI-ESCD Skin Allergy Meeting (SAM) 2025: Pioneering Innovations in Skin…

EAACI-ESCD Skin Allergy Meeting (SAM),Europe's leading event dedicated to skin allergies. This year, SAM 2025 will take place in person inBilbao, Spain, from March 27th to 29th, providing a unique platform for clinicians, researchers, and healthcare professionals to explore the latest breakthroughs and advancements in skin allergy research, diagnosis, and treatment.The meeting's opening day will feature an excitingJoint SessionbySociedad Española de Alergología e Inmunología...
Nasdaq GlobeNewswire
04/02/2025

Implantica announces completion of first GI-focused RefluxStop™ educational…

During this meeting, the surgeons from Chelsea & Westminster Hospital and a group of 11 gastroenterologists from the region spent the evening discussing RefluxStop's mode of action, patient selection, and reviewing robust clinical data from hundreds of patients. During this meeting, the surgeons from Chelsea & Westminster Hospital and a group of 11 gastroenterologists from the region spent the evening discussing RefluxStop's mode of action, patient selection, and reviewing robust…
PR Newswire
04/02/2025

Coloplast A/S - Interim Financial Report, Q1 2024/25

2024/25Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin 1of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%.Growth in Chronic Care was driven...
Nasdaq GlobeNewswire
04/02/2025

NICE Recommends Cytisine (Cytisinicline) Within The Treatments "More Likely" To…

"Cytisine is a real game-changer for smoking cessation," said Beverley Bostock, Advanced Nurse Practitioner, Mann Cottage Surgery, Gloucestershire. "Cytisine offers a short treatment duration compared to many other available treatments, and has a proven track record, making it a practical and effective option. With NICE's updated guidelines in place, clinicians will freely be able to provide this treatment option, where appropriate, to support more individuals in breaking free…
PR Newswire
04/02/2025

Fagron solidifies its leadership position with the acquisition of Guinama in…

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 4 Feb 2025 – 7AM CET Fagron solidifies its leadership position with the acquisition of Guinama in SpainFagron, the leading global player in pharmaceutical compounding is pleased to announce the acquisition of Guinama in Spain. This acquisition underscores Fagron's commitment to expanding across our key markets whilst adhering to our disciplined acquisition strategy.Guinama,based in Valencia, Spain, specializes in...
Nasdaq GlobeNewswire
04/02/2025
Altri  Comunicati